EGFR and non-small cell lung carcinoma: In conclusion, we found that NSCLC patients with EGFR mutations who were diagnosed with PD during treatment with afatinib as a first-line EGFR-TKI acquired T790M at a frequency similar to that previously revealed for such patients treated with first-generation EGFR-TKIs.